Abstract
The association between diabetes mellitus and coronary artery disease (CAD) is wellknown. Being the leading cause of death in diabetics, CAD is a target for prevention, diagnosis and treatment. In that sense, silent CAD in diabetics has long been a matter of concern, leading both to continued attempts at its diagnosis as well as to the persisting challenge of defining if screening for CAD in the diabetic population is useful and/or warranted.
The most frequent and stronger point in favor of screening rests on the assumption that early diagnosis of CAD may lead to early treatment and therefore improved outcomes. Nonetheless, screening for CAD in diabetics is a controversial issue, since studies have not yielded evidence supporting better outcomes in diabetics screened for CAD compared to nonscreened diabetics. For several reasons, current tests that detect inducible ischemia or assess atherosclerotic burden may not be able to identify those patients at increased risk. Therefore a cautious look should be taken (once more) at that question.
Keywords: Coronary artery disease, diabetes mellitus, screening, silent ischemia, myocardial perfusion scintigraphy, coronary artery computed tomography.
Current Diabetes Reviews
Title:Screening for Silent Coronary Artery Disease in Diabetics- or Not?
Volume: 11 Issue: 2
Author(s): Andrea De Lorenzo
Affiliation:
Keywords: Coronary artery disease, diabetes mellitus, screening, silent ischemia, myocardial perfusion scintigraphy, coronary artery computed tomography.
Abstract: The association between diabetes mellitus and coronary artery disease (CAD) is wellknown. Being the leading cause of death in diabetics, CAD is a target for prevention, diagnosis and treatment. In that sense, silent CAD in diabetics has long been a matter of concern, leading both to continued attempts at its diagnosis as well as to the persisting challenge of defining if screening for CAD in the diabetic population is useful and/or warranted.
The most frequent and stronger point in favor of screening rests on the assumption that early diagnosis of CAD may lead to early treatment and therefore improved outcomes. Nonetheless, screening for CAD in diabetics is a controversial issue, since studies have not yielded evidence supporting better outcomes in diabetics screened for CAD compared to nonscreened diabetics. For several reasons, current tests that detect inducible ischemia or assess atherosclerotic burden may not be able to identify those patients at increased risk. Therefore a cautious look should be taken (once more) at that question.
Export Options
About this article
Cite this article as:
Lorenzo De Andrea, Screening for Silent Coronary Artery Disease in Diabetics- or Not?, Current Diabetes Reviews 2015; 11 (2) . https://dx.doi.org/10.2174/1573399811666150108122443
DOI https://dx.doi.org/10.2174/1573399811666150108122443 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Treating Obesity: Pharmacology of Energy Expenditure
Current Drug Targets Reacting to Stress: Radical Cellular Pathways for Novel Drug Development
Current Neurovascular Research Towards Newer Molecular Targets for Chronic Diabetic Complications
Current Vascular Pharmacology 2,4-Thiazolidinediones as PTP 1B Inhibitors: A Mini Review (2012-2018)
Mini-Reviews in Medicinal Chemistry Fetal Mechanisms That Lead to Later Hypertension
Current Drug Targets Use of Biguanides and the Risk of Colorectal Cancer: A Register-Based Cohort Study
Current Drug Safety Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Clinical Experience with the Use of Angiotensin Receptor Blockers in Patients with Cardiovascular, Cerebrovascular and Renal Diseases
Current Clinical Pharmacology Advances in Structural Modifications and Biological Activities of Berberine: An Active Compound in Traditional Chinese Medicine
Mini-Reviews in Medicinal Chemistry Prevention of Renal Complications Induced by Non- Steroidal Anti-Inflammatory Drugs
Current Medicinal Chemistry Curcumin: A Natural Product for Diabetes and its Complications
Current Topics in Medicinal Chemistry Dietary Factors Influencing Magnesium Absorption in Humans
Current Nutrition & Food Science Diabetes Care: Risk Factors, Prediction, Prevention, and Individualized Treatment
Infectious Disorders - Drug Targets Effectiveness of Passion Fruit Peel Flour (Passiflora edulis L.) versus Turmeric Flour (Curcuma longa L.) on Glycemic Control: Systematic Review and Meta-Analysis
Current Diabetes Reviews Clozapine Safety, 35 Years Later
Current Drug Safety Cardiac Protection via Metabolic Modulation: An Emerging Role for Incretin-Based Therapies?
Cardiovascular & Hematological Agents in Medicinal Chemistry Infant Breast-Feeding and Suppression of Biomarkers of Future Cardiovascular Disease
Current Nutrition & Food Science Adrenomedullin: Exciting New Horizons
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Prediction of Degeneration of Native and Bioprosthetic Aortic Valves:Issue-Related Particularities of Diabetes Mellitus
Infectious Disorders - Drug Targets Cell Death in Mammalian Development
Current Pharmaceutical Design